Literature DB >> 11414431

Successful prophylaxis of intracranial hemorrhage in infants with severe congenital factor VII deficiency.

S Kankirawatana1, C Mahasandana, G Veerakul, J Seeloem, L Suwantol, V Tanphaichitr, V Suvatte.   

Abstract

During the period 1984-1992, 2 severe cases (1 male, 1 female) of congenital F VII deficiency with intracranial hemorrhage (ICH) were referred to the Department of Pediatrics, Siriraj Hospital Bangkok, Thailand at the ages of 1 and 3 months old. They both responded very well to fresh frozen plasma (FFP) transfusion therapy. Subsequently, both had repeated episodes of ICH (repeated ICH) 5 and 6 times, despite the 10-14 days of replacement therapy for each episode and eventually died at the ages of 11 and 13 months. Since September 1996, another 2 severe cases (2 females) of congenital F VII deficiency who had ICH within their first month of life were referred to us. In order to prevent repeated ICH, we started a prophylactic regime after the second episode of ICH, by giving FFP 10 ml/kg twice a week. The average duration of follow up was 21 months (at 8 and 34 months). All of them (aged 14, and 38 months old) are doing well at this time and free from repeated ICH. From this observation, if there is FFP available, this regime is an effective way to prevent repeated ICH in infants with severe congenital Factor VII deficiency.

Entities:  

Mesh:

Year:  2000        PMID: 11414431

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  1 in total

1.  Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER).

Authors:  Mariasanta Napolitano; Muriel Giansily-Blaizot; Alberto Dolce; Jean F Schved; Guenter Auerswald; Jørgen Ingerslev; Jens Bjerre; Carmen Altisent; Pimlak Charoenkwan; Lisa Michaels; Ampaiwan Chuansumrit; Giovanni Di Minno; Umran Caliskan; Guglielmo Mariani
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.